Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
AxoGen, Inc.
AXGN
NASDAQ·Healthcare·Medical - Devices·Mkt cap $2.3B
$45.89
▲ +4.25%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.71 - $46.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 298.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary processed human nerve allograft technology eliminating need for autografts and secondary surgical sites
- Comprehensive product portfolio addressing multiple aspects of peripheral nerve repair and protection
- Established relationships with key surgical specialties and military hospital networks
- Regulatory clearances and market presence across multiple international markets
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Rising incidence of peripheral nerve injuries from trauma, diabetes, and surgical complications
Value
Extreme premium - high expectations embedded
Momentum
Hot
+27.8% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AXGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
APR 28, 2026
Reported EPS of $0.07 vs $0.12 consensus (-41.7% surprise). Revenue of $61.5M vs $57.8M expected (+6.2%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-41.7%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
+15%
+17%
+18%
+24%
+21%
+27%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$47.9M
$48.6M
$49.4M
$48.6M
$56.7M
$60.1M
$59.9M
$61.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-31.9%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$49.00
▲ +6.8% vs $45.89
Latest: Raymond James · $48.00 · Apr 29, 2026
3 analysts covering